ImmunoGen, Inc. develops targeted anticancer therapeutics using our expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents.

We have established expertise in the development and humanization of tumor-targeting antibodies. As is well accepted, engineered antibodies can do an excellent job of selectively binding to cancer cells, but are typically sub-optimal in their ability to actually kill cancer cells. Thus, we have developed specialized cancer-cell killing agents to serve as payloads – to be attached to such antibodies for targeted delivery to tumor cells.

Our payload agents are 1,000-10,000 times more potent than traditional chemotherapy agents. We also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell.

We use our Targeted Antibody Payload (TAP) technology – together with our strong antibody expertise – to develop our own product candidates. We also selectively outlicense our technology to other companies for use with their engineered antibodies.

There are now many TAP compounds in clinical testing through our own product programs and those of our partners. The lead compound – trastuzumab-DM1 (T-DM1) – is in advanced clinical testing by Genentech* and Roche. Next are IMGN901 for CD56+ solid tumors and multiple myeloma and SAR3419 for non-Hodgkin's lymphoma.

ImmunoGen is headquartered in Waltham, Massachusetts. Our GMP manufacturing facility is in Norwood, Massachusetts. We have approximately 200 employees in R&D, clinical research, manufacturing, and administrative functions.

*Genentech is a wholly owned member of the Roche Group.